Thorne is now available in our US and Canadian catalogs!
This protocol was developed for practitioners using Fullscript in the United States and the templates cannot be applied to accounts operating outside of the United States

Tru Niagen® Pro 300

300 mg, once or twice per day, for a minimum 21 days (1)(2)(3)

Tru Niagen® Pro 500

500 mg, once or twice per day, for a minimum 21 days (1)(2)(3)

  • In a double-blind, crossover trial, a single 500 mg dose of nicotinamide riboside reduced oxidative stress markers while increasing NADPH and improved exercise performance in older men. (4)
  • Nicotinamide riboside reduced neurodegeneration in preclinical models of Parkinson’s disease through its ability to restore the health of the mitochondria, the site of reactive oxygen species (ROS) overproduction. (6)
  • A review indicated that nicotinamide riboside could exert beneficial effects in amyotrophic lateral sclerosis (ALS) and Parkinson’s Disease in part through its ability to suppress mitochondrial production of ROS as well as preventing axonal degeneration that occurs due to NAD+ depletion in neurons. (7)
  • Therapies that maintain intracellular NAD(+) pools during conditions of oxidative stress may help block age-dependent cellular damage. (8)
  • Nicotinamide riboside increased levels of NAD+ by 100% and was found to be beneficial in healthy, human volunteers. (9)
  • In a mouse model of diet-induced obesity, oral supplementation with nicotinamide riboside improved oxidative metabolism and increased NAD+ in brown adipose tissue, skeletal muscle, and the liver resulting in enhanced oxidative metabolism and mitochondrial function. (10)

Disclaimer

The Fullscript Integrative Medical Advisory team has developed or collected these protocols from practitioners and supplier partners to help health care practitioners make decisions when building treatment plans. By adding this protocol to your Fullscript template library, you understand and accept that the recommendations in the protocol are for initial guidance and may not be appropriate for every patient.

View protocol in-app
References
  1. https://pubmed.ncbi.nlm.nih.gov/31278280/
  2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702140/
  3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876407/
  4. https://link.springer.com/article/10.1007/s
  5. https://www.sciencedirect.com/science/article/pii/S2211124718307423
  6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016185/
  7. https://pubmed.ncbi.nlm.nih.gov/18522897/
  8. https://pubmed.ncbi.nlm.nih.gov/29211728/
  9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3616313/